(Reuters) -The Bank of Japan kept interest rates steady on Thursday, as policymakers preferred to tread cautiously in pushing up borrowing costs amid uncertainty over U.S. president-elect Donald Trump’s economic plans. As widely expected, the nine-member BOJ board decided to keep its short-term policy rate unchanged at 0.25%. But hawkish board member Naoki Tamura dissented and proposed raising interest rates to 0.5% on the view inflationary risks were building. His proposal was voted down. QUOTES: BART WAKABAYASHI, TOKYO BRANCH MANAGER, STATE STREET, TOKYO “They probably want to wait till next year and want some more solid information coming in on…
Author: user
By Ankur Banerjee SINGAPORE (Reuters) -Asian stocks slipped and the dollar was perched near a two-year high on Thursday after the U.S. Federal Reserve cautioned it would ease the pace of rate cuts in the coming year, while the Bank of Japan kept rates steady, as expected. The yen weakened to touch a one-month low of 155.43 per dollar after the decision. The yen is down more than 8% this year against the dollar and is set for a fourth straight year of decline. The BOJ’s decision comes as the yen hovers around the 155 per dollar mark, the weaker…
The Bank of Japan (BOJ) headquarters is seen beyond the cherry blossoms in Tokyo on March 20, 2023.Kazuhiro Nogi | Afp | Getty ImagesThe Bank of Japan on Thursday held its benchmark interest rate steady at 0.25%.The decision comes a day after the U.S. Federal Reserve cut rates by 25 basis points, bringing the federal funds rate to 4.25%-4.5%.The yen weakened 0.16% against the dollar after the rate decision, trading at 155.06.The BOJ said in its statement that the decision to hold was a split 8-1 decision, with board member Naoki Tamura advocating for a 25-basis-points hike.The central bank did…
By Rae Wee SINGAPORE (Reuters) -The dollar flirted with a two-year peak on Thursday after the Federal Reserve signalled a slower pace of rate cuts in 2025, while the yen blipped lower after the Bank of Japan (BOJ) stood pat on rates. The BOJ kept interest rates steady on Thursday as expected, underscoring policymakers’ preference to spend more time scrutinising whether wage hikes will broaden and keep inflation durably around its 2% target. The yen fell in the immediate aftermath of the decision, weakening roughly 0.3% against the dollar to a one-month low of 155.28, before paring some of those…
SEATTLE—HomeStreet, Inc. (NASDAQ:) director Sidney Craig Tompkins (NYSE:) recently made a significant purchase of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Tompkins acquired 5,000 shares on December 17, 2024, at an average price of $11.4925 per share. The total value of the transaction amounted to approximately $57,462. The purchase comes as HomeStreet trades at a price-to-book ratio of 0.38, significantly below historical averages according to InvestingPro data. Following this purchase, Tompkins holds 5,000 shares indirectly through a defined benefit plan, as noted in the filing. Additionally, Tompkins has direct ownership of…
In recent transactions, American Strategic Investment Co. (NYSE:NYC) saw significant stock purchases by Nicholas S. Schorsch and affiliated entities. On December 16, 17, and 18, a total of 2,517 shares of Class A common stock were acquired, amounting to $22,451. The purchases were made at prices ranging from $8.78 to $9.01 per share. According to InvestingPro data, the company currently trades at a significant discount to its Fair Value, though it maintains a weak overall financial health score. Nicholas S. Schorsch, a prominent figure in the company, is the sole managing member of Bellevue Capital Partners (WA:), LLC, which is…
The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 focus session on advances in fat reduction therapies and further detailed in the Non-surgical Body Contouring session through an oral presentation.The CBL-0204 Phase 2b results underscore the remarkable efficacy and safety profile of CBL-514 for localized adipose reduction. Both primary and secondary endpoints were met, establishing CBL-514 as the potentially first injectable therapy for large-area fat reduction. This trial was also the first trial adopted FDA-recommended metrics, including…
SAN DIEGO—Allan Camaisa, CEO and Chairman of the Board at Calidi Biotherapeutics, Inc. (NASDAQ:CLDI), recently sold 10,000 shares of the company’s common stock. The shares were sold at a price of $1.62 each, amounting to a total transaction value of $16,200. Following this sale, Camaisa holds 66,712 shares directly. The transaction comes as CLDI shares have declined nearly 89% year-to-date, with the stock currently trading at $1.44. According to InvestingPro analysis, the company appears undervalued at current levels. The transaction was reported for tax planning purposes, according to a footnote in the filing. Despite the sale, Camaisa retains significant potential…
Some stocks occasionally experience significant price drops due to shortsighted reasons. When that happens, it presents an excellent opportunity for careful and patient investors to buy the dip. Other times, shares of companies move in the wrong direction for good reasons. In those cases, it is generally best to stay away unless there are good reasons to think the corporation in question can overcome whatever headwinds it is facing. That brings leads to fuboTV (NYSE: FUBO) and Chegg (NYSE: CHGG), which have significantly lagged the market over the past two years. Both are now penny stocks, but even though they…
New York, New York–(Newsfile Corp. – December 18, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Unisys Corporation (NYSE: NYSE:) resulting from allegations that Unisys may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Unisys securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. To join the prospective class action,…